SymbolGRMLW
NameKLOTHO NEUROSCIENCES, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address1300 SOUTH BOULEVARD,SUITE D, CHARLOTTE, North Carolina, 28203, United States
Telephone+1 833 931-6330
Fax
Email
Websitehttps://www.klothoneuro.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001907223
Description

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimers and Parkinsons Disease, multiple sclerosis and rare neurodegenerative diseases. The companys current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

Additional info from NASDAQ:
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimers and Parkinsons Disease, multiple sclerosis and rare neurodegenerative diseases. The companys current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

2026-08-11 13:00

Greenland Mines Arrives at Skaergaard, Commences Drilling as 2026 Field Season Moves into Full Operation

Read more
2026-08-10 15:36

(99% Neutral) KLOTHO NEUROSCIENCES, INC. (GRMLW) Announces Regulatory Update

Read more
2026-07-31 13:00

Greenland Mines Departs for Skaergaard – Expanded 2026 Program Targeting Next Phase of Development

Read more
2026-07-28 13:00

Biotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer’s and Aging

Read more
2026-07-23 14:00

This Greenland Rare Earth and Precious Metals Company Just Put Up a Takeover Defense, and It Says Something About How It Views Its Own Value

Read more
2026-07-23 13:34

Sawyer Jason David 🟢 acquired 240.0K shares of Greenland Mines Ltd (GRML) at $0.23 Transaction Date: Jul 22, 2026 | Filing ID: 080657

Read more
2026-07-23 13:00

(99% Neutral) KLOTHO NEUROSCIENCES, INC. (GRML) Announces Business Combination

Read more
2026-07-23 13:00

Greenland Mines Announces Limited-Duration Stockholder Rights Plan Intended to Protect Shareholder Value

Read more
2026-07-23 10:00

New Form 8-A12B - Greenland Mines Ltd <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001213900-26-080648 <b>Size:</b> 297 KB

Read more
2026-07-21 20:30

(99% Neutral) KLOTHO NEUROSCIENCES, INC. (GRMLW) Announces Regulatory Update

Read more